In fact, U.S. comparison can be detrimental to Canada because the fees are roughly the same in the U.S. and in Canada except that the market is 10 times smaller here. The cost of getting the drug to market, with this fee structure, is disproportionate in Canada.
On February 7th, 2019. See this statement in context.